newsfilter
← Latest News
Business Wire·

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines